adis.com

Learn more

Essential reading for healthcare providers including specialists, hospital physicians, general practitioners, nurses, pharmacists, clinical pharmacologists, formulary decision-makers, payers, and university and healthcare researchers. These journals offer: • Large and global readership* • Impact factors and discoverability • Thorough peer review and efficient processes • Accelerated publication options • A publishing solution for every scientifically sound article

*Geographic distribution approximately 1/3 Americas, 1/3 EMEA, 1/3 Asia and ROW.

Publishing with AdisWe are committed to making the publication process as efficient as possible for our authors.

All Adis journals welcome pre-submission enquiries, accept original research and reviews, and welcome submissions of all types of studies (positive, negative or confirmatory).

We aim to find a journal for all research deemed sound by peer review. We will endeavor to cascade articles to an alternative, more suitable journal in the portfolio, if the manuscript cannot be accommodated in the original journal to which it was submitted.

Adis endorses the ICMJE / WAME / COPE Guidelines for Journal Editors, and encourages all manuscripts reporting sponsored research to comply with Good Publication Practice (GPP).

Adis also publishes books. To discuss any book ideas please contact our Editors at books@adis.com, or visit our website, adis.com/books. We also develop custom book derivatives. Please visit our website, thinkingoutsidethebook.co.uk, for examples, or contact christopher.watson@springer.com for further information.

If you would like to find out more about publishing with Adis, visit adis.com/PublishingSolutions or contact:

Alessandro Gallo Springer Healthcare Italia Tel. +39 0254259721 alessandro.gallo@springer.com

Find out more

Adis JournalsPremier collection of drug-focused medical journalsPublishing definitive research and reviews on drugs, devices and other interventions

blurb

2

Journal Title Impact Factor

Indexing ***

Features Description

Advances in Therapy

2.272 Medline An international journal dedicated to rapid publication of studies in clinical medicine across all therapeutic areas and medical interventions related to drugs and devices. Extensive editorial board. Section leads include: R. Rizzoli (Rheum), R. McIntyre (Psych), I. Menown (Cardio), C. Twelves (Onc), A. Veves (Diabetes), K. Beeh (Resp)

American Journal of Cardiovascular Drugs

2.422 Medline Open ChoiceAdis Drug Evaluations

Promotes rational therapy and effective patient management in cardiovascular medicine. Publishes reviews and original research articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established drugs, devices, and other interventions. Editor-in-Chief: Amitabh Prakash

American Journal of Clinical Dermatology

2.725 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI

Promotes rational therapy and effective patient management in dermatology. Publishes reviews and original research articles covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures. Editor-in-Chief: Kathy Fraser

Applied Health Economics & Health Policy

1.710* Medline Open Choice Publishes original research and review articles on the economic implications of healthcare interventions, economic consequences of policy initiatives, and analyses of pricing and reimbursement systems. Of high interest to healthcare payers and providers, health economists and outcomes researchers, and healthcare policy and decision-makers. Editor-in-Chief: Tim Wrightson

BioDrugs 2.989 Medline Open ChoiceAdis Drug Evaluations

Publishes original research and reviews of the latest developments in the clinical application of biotechnology for the treatment of human disease, including aspects of target selection, drug development and delivery, and clinical use of biologics and molecularly targeted therapeutics. Editor-in-Chief: Joanne Beachman

Cardiology and Therapy

N/A PubMed Open accessRapid+ Service

Publishes papers in all areas of cardiology, including interventional cardiology, acute coronary syndrome, arrhythmia, stroke/atrial fibrillation and thrombosis, diabetes, electrophysiology, heart failure, hypertension, imaging, intervention/surgery, lipid metabolism, and prevention and management of cardiovascular disease, and device-related therapies. Editors-in-Chief: Robert Giugliano (USA), Uwe Zeymer (Europe), Ian Menown (Interventional)

Clinical Drug Investigation

1.557 Medline Open ChoiceAdis Drug Evaluations

Publishes original research covering all phases of clinical drug development and therapeutic use of drugs and drug devices, as well as pharmacoeconomic and outcomes research, across all therapeutic areas. Editor-in-Chief: Jasbir Singh

Clinical Pharmacokinetics

5.053 Medline Open ChoiceTop 50 ISI

Promotes continuing development of clinical pharmacokinetics and pharmacodynamics to optimize drug therapy, and to further postgraduate education in clinical pharmacology and therapeutics. Editor-in-Chief: Amitabh Prakash

CNS Drugs 5.113 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI

Promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology. Publishes reviews and original research articles covering important issues in the drug treatment of psychiatric and neurological disorders. Editors-in-Chief: Kate Palmer, Sue Pochon

Dermatology and Therapy

1.242* PubMed

Medline due 2016

Open accessRapid+ Service

Covers all clinical aspects of dermatology including skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of esthetic dermatology, including skin maintenance, dermatological surgery, and lasers and other device-related therapies. Editors-in-Chief: Alan Menter (USA), Richard Warren (Europe)

Diabetes Therapy 2.915* PubMed

Medline due 2016

Open accessRapid+ Service

Focuses on cutting-edge research in the prevention, treatment, management, and education of diabetes and related disorders, including obesity and metabolic syndromes, as well as device-related therapies. Editors-in-Chief: Fernando Ovalle (USA), Marc Evans (Europe)

Open ChoiceRapid+ Service

*Article processing charge applies for Open Choice/Open Access; additional charges apply for Rapid+ Service and VIP Service

Feature Description

Open Choice*Our Open Choice program allows authors to publish open access in the Adis subscription-based journals. Open Choice articles are freely available online immediately upon publication, clearly labelled on SpringerLink using an open access button, with authors retaining non-commercial copyright. Open Choice articles are automatically exported to PubMed Central/Europe PubMed Central.

Open Access*Fully open access journal with unrestricted online access. Authors retain non-commercial copyright to their work, and all articles comply with open access mandates, including re-use and immediate deposit of final article version in any repository.

Key for contents of the tables featured on pages 2, 3 and 4

Journal Title Impact Factor

Indexing ***

Features Description

Drug Safety 2.824 Medline Open ChoiceTop 50 ISI

Advances the rational use of pharmacotherapy by publishing reviews and original research articles offering guidance for safe and effective drug utilization and prescribing. Of high interest to healthcare professionals, regulators, and pharma industry personnel with an interest in drug safety, pharmacovigilance and pharmacoepidemiology. Editor-in-Chief: Nitin Joshi

Drug Safety – Case Reports

N/A PubMed due 2015**

Open access Specializes in the publication of case reports and case series relating to suspected adverse drug reactions, as well as reports of any unintended or adverse effects following administration of a medicinal product (or products). The journal welcomes reports of cases involving ‘near misses’ (for example, medication errors detected before harm is done), and cases involving the lack of efficacy of a therapeutic product. Editors: N. Joshi; S. McMillan

Drugs 4.343 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI

Promotes optimum pharmacotherapy by publishing reviews covering the most important aspects of clinical pharmacology and therapeutics. Drugs also includes Adis Drug Evaluations, current reviews on drugs receiving a first global approval, and original research articles reporting pivotal late-phase clinical trials. Editor-in-Chief: Dene Peters

Drugs & Aging 2.838 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI

Promotes optimum drug therapy in older adults through reviews and original research articles covering the most important aspects of clinical pharmacology and patient management in this patient group. Physiological changes during aging that have implications for drug therapy also fall within the scope of the journal. Editor-in-Chief: David Williamson

Drugs & Therapy Perspectives

N/A N/A Open Choice Concise, authoritative guidance on the choice and clinical use of drugs for all healthcare professionals. The journal includes differential features tables, step-by-step patient care guidelines, overviews of drugs and their place in therapy, questions and answers on the clinical use of drugs, current thinking on disease management, clinically useful pharmacodynamics and pharmacoeconomics, hot topics in adverse drug reactions and drug interactions, and incorporates international and national viewpoints. Editor-in- Chief: Katherine Lyseng-Williamson

Drugs in R&D 1.310* Medline Open access Publishes clinical research on both new and established drugs, and preclinical research of direct relevance to clinical drug development, in all therapeutic areas. Original research, reviews and case reports are welcomed. Editor-in-Chief: Anton van Rensburg

Drugs – Real World Outcomes

N/A PubMed due 2015**

Open access Targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related ‘big data’. Has a broad scope, encompassing studies investigating drug utilization, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness, and economic analyses. Editor-in-Chief: Dene Peters

European Journal of Drug Metabolism and Pharmacokinetics

Volume 39 · Number 3 · September 2014

13318European Journal of D

rug Metabolism

and Pharmacokinetics

Volume 39 • N

umber 3 • Septem

ber 2014 • pp. 155–230

Volume 39 • Number 3 • September 2014

European Journal of

DRUG METABOLISM and PHARMACOKINETICS

ORIGINAL PAPERS

Infl uence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotineW. Cawello · A. Fichtner · H. Boekens · M. Braun 155

The study of absorption kinetics of berberine based on portal vein in rat, and the infl uence of verapamil and borneol to its absorption ability by UHPLC methodL. Zou · R. Li · P. Wang · Y. Xiao · L.-J. Xu · Y.-X. He · G. Zhao · L.-X. Peng 165

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteersB.E. Miller · K. Smart · S. Mistry · C.L. Ambery · J.C. Bloomer · P. Connolly · D. Sanderson · T. Shreeves · R. Smith · A.L. Lazaar 173

Preparation and in vitro/in vivo evaluation of felodipine nanosuspensionB.P. Sahu · M.K. Das 183

Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9K. Yamamoto · M. Mukai · K. Nagaoka · K. Hayashi · H. Hichiya · K. Okada · M. Murata · M. Shigeyama · S. Narimatsu · N. Hanioka 195

Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogsW. Cong · L. Shen · D. Xu · L. Zhao · K. Ruan · Y. Feng 203

Changes in the expression levels of tight junction components during reconstruction of tight junction from mucosal lesion by intestinal ischemia/reperfusionY. Takizawa · H. Kishimoto · M. Tomita · M. Hayashi 211

SHORT COMMUNICATION

The infl uence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5W.J. Hua · W.X. Hua · F.Y. Nan · W.A. Jiang · C. Yan 221

Abstracted/Indexed in: Science Citation Index Expanded (SciSearch), PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, CAB International, Biological Abstracts, BIOSIS, CAB Abstracts, Derwent Drug File, Elsevier Biobase, Global Health, IBIDS, Journal Citation Reports/Science Edition, OCLC, PASCAL, SCImago, Summon by Serial Solutions

Instructions for Authors for Eur J Drug Metab Pharmacokinet are available at link.springer.com/13318

European Journal of Drug Metabolism and Pharmacokinetics

1.563 Medline Open Choice Publishes original research and reviews addressing all aspects of preclinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy, and pharmacokinetic modelling. Editor-in-Chief: Jasbir Singh

High Blood Pressure and Cardiovascular Prevention

1.200* Medline Open Choice Provides an open and dynamic forum for discussing current topics in both hypertension and cardiovascular disease prevention. Content includes original research and reviews, expert commentary on guidelines, clinical trials and experimental research, insights into socio-economic issues around cardiovascular disease, and proceedings of scientific meetings. Editor-in-Chief: Massimo Volpe

Infectious Diseases and Therapy

N/A PubMed

Medline due 2016

Open accessRapid+ Service

Addresses all aspects of infectious disease therapies. Areas of focus include, but are not limited to, microbiology, virology, HIV/AIDS, vaccines, drug-resistant pathogens, fungal infections, chronic infections, and tropical, emergent, pediatric, dermal, and sexually-transmitted diseases, and device-related therapies. Editors-in-Chief: Michael Rybak (USA), Alex Soriano (Europe)

Molecular Diagnosis & Therapy

2.891 Medline Open ChoiceAdis Drug Evaluations

Publishes original research and reviews providing insights into molecular diagnostic and pharmacogenomic techniques and their use in personalized medicine by linking diagnostic and prognostic biomarkers to appropriate therapy, and emphasizing the development of diagnostic/therapeutic products for use in drug development and therapeutic decision-making. Editor-in-Chief: Alison Fitches

Feature Description

Rapid+ Service*All papers receive rapid publication and concierge service including:• 10-day peer review. A faster service may be possible with advanced notice• 22 days from submission to online publication of pre-typeset manuscript with DOI, allowing authors 1 week for incorporation

of peer review comments. 30 days from submission to finalized online publication• Dedicated support from pre-submission to post-publication. This includes assistance with submission, restyling, development of

enhanced content (a summary slide is published alongside every article; in addition, video abstracts, audioslides, slide decks, videos and animations may also be included), and provision of regular updates on manuscript progress and metrics. Comprehensive technical edits are also provided, ensuring a consistent and accurate final article

Adis Drug EvaluationsDefinitive Adis-authored reviews of both newer and established drugs and their place in patient management.

Top 50 ISIRanked in top 50 of relevant ISI category.

3

4

* SCImago Cites per Doc (2y): this uses the same formula as Impact Factor but is based on the Scopus database (www.scimagojr.com) | ** Application following publication of 15 articles*** Adis journals are also included in a wide range of other abstracting/indexing services. See journal website for details

Journal Title Impact Factor

Indexing ***

Features Description

Neurology and Therapy

N/A PubMed Open accessRapid+ Service

Publishes clinical insight into common diseases, developmental, degenerative and neuropsychiatric disorders; and therapeutic treatments such as anesthetics, analgesics, anticonvulsants, antidepressants, antipsychotics, hypnotics/sedatives, mood stabilizers, stimulants, and neurosurgery and device-related therapies. Editorial Board includes Paul Francis (UK), Hans-Peter Hartung (Germany), Olivier Rascol (France), Heinz Reichmann (Germany), Tony Shapira (UK) and Eugen Trinka (Austria)

Ophthalmology and Therapy

N/A PubMed Open accessRapid+ Service

Focuses on the use of ophthalmological therapies, devices, and surgical techniques. Areas of focus include presbyopia, macular degeneration, glaucoma, diabetic retinopathy, macular edema, conjunctivitis, dry eye, ocular hypertension, and ocular allergy. Editors-in-Chief: Terrence P. O’Brien (USA), Anthony Bron (Europe)

Pain and Therapy N/A PubMed Open accessRapid+ Service

Publishes papers that discuss pain therapies and pain-related devices. Areas of focus include, but are not limited to, cancer, lower back, migraine, neuropathic, osteoarthritic, postoperative, acute, moderate-to-severe, and chronic pain. Co-Editor-in-Chief: S. Passik; G. Varrassi

Pediatric Drugs 1.975 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI

Promotes the optimization and advancement of all aspects of pediatric pharmacotherapy and clinical pharmacology. Timely reviews and original research articles provide healthcare decision-makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology, and the care of children and adolescents. Editor-in-Chief: Rod McNab

Pharmaceutical Medicine

0.553* Medline due 2016

Open Choice Promotes the multidisciplinary specialty of pharmaceutical medicine, providing original research and reviews for professionals working in the pharma industry and related fields, and encompassing scientific/medically related activities in the discovery, development, evaluation, registration, and monitoring of medicines. Editor-in-Chief: Sue Pochon

Pharmaco- Economics

2.450 Medline Open ChoiceTop 50 ISI

Promotes the continuing development and study of health economics, pharmacoeconomics and quality-of-life assessment as applied to optimum drug therapy and health outcomes, providing a practical economic background to informed clinical prescribing decisions, and allocation of healthcare resources, especially for healthcare professionals involved with healthcare policy and decision-making. Editors: C.I. Carswell; T. Wrightson

Pulmonary Therapy

N/A PubMed due 2016**

Open accessRapid+ Service

Covers all areas of pulmonary medicine, including: asthma; COPD; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other allergies; influenza, pneumococcal infection, RSV and other respiratory infections; and inhalers and other device therapies. Editor-in-Chief: Kai Beeh (Europe)

Oncology and Therapy

N/A PubMed due 2016**

Open accessRapid+ Service

Aims to disseminate research on diagnosis and management of rare cancers, including rare skin cancers and non-cutaneous melanoma, thoracic, urogenital, male and female genital, neuroendocrine, endocrine, CNS, sarcomas, digestive tract, head and neck, pediatric, and hematological malignancies, and device-related therapies.

Rheumatology and Therapy

N/A PubMed due 2015**

Open accessRapid+ Service

Covers all areas of rheumatology and conditions treated by rheumatologists including RA, gout, gouty arthritis, psoriatic arthritis, osteoarthritis, juvenile idiopathic/rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, Pompe’s disease, inflammatory joint conditions, musculoskeletal conditions, systemic sclerosis and fibromyalgia, and device-related therapies. Editorial Board includes E.C. Keystone (Canada), R. Rizzoli (Switzerland), P. Helliwell (UK), J.M. Davis (USA) and F. Perez-Ruiz (Spain)

Targeted Oncology

4.000 Medline Open ChoiceAdis Drug Evaluations

Focuses on insights into the basic science of cellular functions through the publication of orig-inal research and critical reviews of clinical data. This journal is for oncologists, other healthcare professionals and scientists committed to improving outcomes in patients with cancer. Editor-in-Chief: Natalie Carter

The Patient: Patient-Cen-tered Outcomes Research

1.902 Medline Open ChoiceTop 50 ISI

Focuses on the study of outcomes research to enhance therapy in a patient-centered manner. The journal aims to provide original research and reviews examining the needs, values and role of the patient in an increasingly complex healthcare landscape, in which funding and decision-making are requiring ever-greater awareness of the patient’s perspective. Editor-in-Chief: Chris Carswell